Long-Term Assessment of Safety and Physical Function With AMG 108 in RA

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess long-term safety of SC AMG 108 in the treatment of RA

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Only subjects eligible for and completing 24 weeks of study 20050168 will be permitted to enroll.

Exclusion Criteria:

• Subjects not eligible for or not completing 24 weeks of study 20050168 will be excluded.